27 results about "Attention deficit hyperactivity disorder" patented technology

The invention relates to the technical field of attention deficit hyperactivity disorder detection, and discloses a device for detecting cognitive and developmental conditions of children with hyperactivity disorder, which comprises a handle, a head-mounted device, a bracelet, a hierarchical adaptive algorithm module, a multi-dimensional execution module and a data fusion and analysis module, a multi-mode sensing module is arranged in each of the handle, the head-mounted device and the bracelet; a motion capture unit, a high-sensitivity key array, a tactile feedback module and a wireless transmission module are integrated in the handle, and a wireless electroencephalogram acquisition module, a miniature near infrared spectrum module and an eye movement tracking module are integrated in the head-mounted device. According to the invention, through deep fusion of a multi-dimensional cognitive evaluation system and gamepad hardware, the device not only breaks through the limitation of the traditional neuropsychological test in methodology, but also realizes refined capture of ADHD heterogeneity characteristics in the technical level, and provides a hardware basis for establishing an objective and quantitative diagnostic tool with high ecological efficiency.

The invention relates to the field of medical image analysis and neuropsychiatric disease diagnosis, and particularly discloses a brain network typing diagnosis system and method for attention deficit hyperactivity disorder. Comprising a data acquisition and preprocessing module, a topological feature extraction module, a supervised manifold learning module, a network reconstruction and diagnosis module, a parameter optimization module and a result verification module, continuous homology analysis is performed on a brain region function connection matrix based on an algebraic topology theory, and a brain region topological feature matrix is generated; utilizing supervised manifold learning to map the brain region topological feature matrix to a Riemannian manifold, and calculating a brain region importance weight map based on ADHD phenotypic features as supervised signals; according to the method, the brain network is subjected to subtype specific reconstruction through the curvature flow theory of Riemannian geometry, the topological difference between different subtypes is calculated, accurate typing diagnosis of ADHD is achieved, and the diagnosis accuracy is improved by 15%-20%.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

The present invention relates to a system and method for real-time screening of Attention Deficit Hyperactivity Disorder using electroencephalographic signals processed through a GPU-accelerated time-frequency inference architecture. The invention enables continuous acquisition of multi-channel electroencephalographic data, adaptive preprocessing for artifact suppression and signal stabilization, and parallel execution of time-frequency transformations to extract neurologically relevant features in real time. Extracted features are analyzed using an inference process configured to identify neurological patterns associated with Attention Deficit Hyperactivity Disorder, while continuous validation of signal quality and temporal consistency ensures diagnostic reliability. The system dynamically adapts analytical parameters based on evolving signal characteristics and regulates computational workload to achieve energy-efficient operation during prolonged monitoring. The invention provides a technically integrated, machine-implemented screening solution capable of delivering reliable, real-time neurological assessment suitable for clinical environments.

The present invention relates to an improved method for the preparation of optically pure (S)-biloxazine or a salt thereof. The (S)-biloxazine prepared according to the preparation method of the present invention can be selectively administered to prevent or treat attention deficit hyperactivity disorder (ADHD). Accordingly, the dosage of a drug can be reduced by half or more, and side effects can be reduced.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

Contemplated test kits, diagnostic apparatus and methods using same for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Kits and diagnostic apparatus include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

The application discloses a game adjusting method and device and a storage medium, and relates to the technical field of games, and can improve the exercise efficiency of attention deficit hyperactivity disorder.

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

The present technology relates to sensory apparatuses that are useful for individuals who need assistance with neurodevelopmental conditions such as autism spectrum disorder (ASD), sensory processing disorder (SPD), attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD). Such apparatuses can include a top cover connected to or integral with a top base plate, and a bottom cover connected to or integral with a bottom base plate, about which projections or wings having different visual or tactile properties, such as different textures, are rotatably attached. The present technology is also directed to systems and methods for the management of a neurodevelopmental condition.

The present invention provides for an oral solution that includes atomoxetine, or pharmaceutically acceptable salt thereof, methods of manufacturing the oral solution, and methods of treating attention deficit hyperactivity disorder (ADHD) in a human subject that include orally administering the oral solution to a human subject in need thereof.

A system for assessing an ADHD status of a subject comprising:(a) receiving circuitry configured to receive a measurement signal including measurements of a plurality of nasal respirations from a sensor configured to sense a nasal respiration of a subject;(b) optional determining circuitry configured to determine values of one or more nasal respiration parameter from said measurement signal;(c) evaluation circuitry configured to evaluate said subject, based on said values of one or more respiration parameter to provide an indication of ADHD status of said subject.

The present application relates to a compound as shown in formula (I), stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, and preparation method and pharmaceutical composition. The compound is an NK-3 receptor antagonist, which can be used for preventing and / or treating depression, anxiety, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory disease, vomiting, preeclampsia, airway related disease, reproductive disorder, contraception and sex hormone dependent disease, gynecological disease related disease, menopausal syndrome related disease.

The present invention relates to the prophylactic and / or therapeutic treatment of a disease selected from the group consisting of long-term COVID disease, myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) disease, fibromyalgia, dementia, neoplastic disease, autoimmune disease, schizophrenia, epileptic seizure disease, excessive inflammatory disease, chronic inflammatory bowel disease, rheumatic disease, obesity, and the like. Hyperuricemia, diabetes (IDDM / NIDDM), acute viral diseases, amyotrophic lateral sclerosis (ALS), bronchial asthma, atopic allergic disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, autoimmune diseases / antibody-related diseases, bipolar affective disorders, celiac disease (CD), chronic obstructive pulmonary disease (COPD), and the like. Chronic inflammatory bowel disease (CED) (i.e. Crohn's disease, ulcerative colitis), cystic fibrosis / cystic fibrosis, depression, endometriosis, polycystic ovarian syndrome, eating disorders, anxiety disorders, addiction disorders, frontotemporal dementia (Pickk's disease), Graves's disease (GD), generalized cardiovascular diseases, Alzheimer's disease, Parkinson's disease, meningitis, multiple sclerosis (MS), and the like. Muscular dystrophy, neurodermatitis, peripheral arterial occlusion disease (PAOD), pneumonia, generalized post-vaccination syndrome and vaccine damage, post-viral infection syndrome, psoriasis, pulmonary arterial hypertension, restless leg syndrome, restrictive pulmonary disease, rheumatoid arthritis (RA), division affective disorder, sepsis, sicca syndrome (SS), scleroderma, and the like. Systemic lupus erythematosus (SLE) and unsatisfactory fertility desires, using an active agent having a nicotinic acetylcholinergic agonist and / or an active agent having a muscarinic acetylcholinergic agonist and / or a muscarinic acetylcholinergic antagonist. This provides a very effective prophylactic and / or therapeutic treatment for these diseases. This prevention or treatment is also readily tolerable, cost effective and easy to apply.

New use of 1-amino-3,5-dimethyladamantane hydrochloride in treating or preventing cognitive impairment, reducing microglia in the cortex and hippocampus, reducing neuron loss in the cortex and hippocampus, and ameliorating the mitochondrial dysfunction state. The cognitive impairment includes cognitive impairment in systemic lupus erythematosus, Parkinson's disease, lateral sclerosis, stroke, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, attention deficit hyperactivity disorder, sepsis-related encephalopathy, or mild cognitive disorder. The present application also provides a corresponding drug and a treatment or prevention method.

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

1. The name of the design product: detection bin. 2. The use of the design product: detection bin for autism and attention deficit hyperactivity disorder detection and auxiliary diagnosis of children. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

The present disclosure relates to the use of inositol-stabilized arginine (“ASI”) for improving cognition. For example, in some implementations, methods include administering an amount of ASI effective to improve cognition in humans. Some embodiments include the use of ASI for improving mental focus and / or attention span. For example, in some implementations, methods include administering an amount of ASI effective to improve mental focus and / or attention span in humans. Some embodiments include the use of ASI for treating and / or preventing cognitive disorders. Cognitive disorders may include stroke, anoxic brain injury, traumatic brain injury, dementia, Alzheimer's disease, Parkinson's disease, MCI, and age-related memory loss, attention deficit hyperactivity disorder (“ADHD”), and other learning disabilities.

The application discloses a VR training system based on the cognitive function defect characteristics of children's attention deficit hyperactivity disorder, relates to the technical field of digital medical treatment, and comprises a data acquisition module, a data evaluation module, a VR training module, a dynamic adjustment module, a result output module and a collaborative work module; the application constructs an objective quantitative model by fusing multi-modal data, accurately identifies three ADHD subtypes and the degree of cognitive defect of each dimension, solves the problem that traditional evaluation is highly subjective, and divides cold / hot executive function double-path training based on the CAPS theory, dynamically customizes task matching according to the subtypes, realizes accurate matching of defects and training, additionally, through real-time monitoring of eye movement and physiological indexes, automatically adjusts task difficulty and feedback strategies, maintains the best challenge level, can effectively improve the participation and training continuity of children, and finally achieves the goal of high-efficiency, high-interest and side-effect-free personalized digital therapy.

The present application relates to the field of detection reagents for neurodevelopmental disorders, and in particular to the application of SCN1A in the preparation of a kit for detecting neurodevelopmental disorders, especially the application of specific multiple mutation sites of the gene. These mutation sites include single nucleotide deletion mutations of chr2:165984651, chr2:165984876 and chr2:165984932, which are associated with attention deficit hyperactivity disorder. The kit provided by the present application combines targeted cleavage and fluorescent PCR amplification technology to improve the detection sensitivity of multiple mutation sites of the SCN1A gene. The kit provided by the present application covers multiple SCN1A gene mutation sites, enhances the comprehensiveness of detection, and recognizes complex mutation individuals through threshold effect, thereby improving the sensitivity and specificity of detection.

A functional near-infrared spectral signal enhancement and classification method based on spatiotemporal autocorrelation and attention encoding is proposed to address the limitations of limited sample size and insufficient generalization ability of classification models in functional near-infrared spectral signal data. This method is applicable to the auxiliary diagnosis of neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD). The method first preprocesses the raw near-infrared spectral data, extracting oxyhemoglobin signals and calculating spatial autocorrelation parameters, channel-level temporal autocorrelation parameters, and the eigenvalue distribution of the functional connectivity matrix. Then, enhanced data is generated based on the spatiotemporal autocorrelation model. Finally, the raw and enhanced data are input into the STEAFNet deep learning model for accurate classification. This invention generates high-quality enhanced data, expands the sample size, and maintains high fidelity. Combined with deep learning, it improves classification accuracy and generalization ability, providing technical support for clinical applications.

The application discloses a brain-computer interface-based attention deficit hyperactivity disorder treatment system, equipment and storage medium, and belongs to the technical field of brain-computer interfaces. The attention deficit hyperactivity disorder treatment system is based on electroencephalogram signal data received by a brain-computer interface-based attention deficit hyperactivity disorder treatment system, and provides a training role through a visual module. The movement of the training role is controlled based on attention values, and the training role control module is further used to provide attention execution training tasks and inhibition training tasks. The system, equipment and medium brain-computer interface of the application have strong interaction, adopt a multi-task training paradigm, make up for the single and boring shortcomings of the prior art, thereby improving the compliance of the trainer, increasing the training frequency, achieving better training effect, and enabling ADHD patients to not only train in a hospital but also train at home, which is more convenient, economical and efficient. In particular for school-age children and adolescents, the training compliance of the patients is greatly improved, and the drop-out rate during training is reduced.

The invention discloses a neurological and mental disease diagnosis method based on a short video. The method comprises the following steps: establishing a sight tracking network CognittionNet; using the attention signals to establish a sample feature vector matrix D of a certain disease patient and a healthy control person; establishing a random forest model RFA by using the D; a short video I (t) of a certain person is collected and sent to the CogntionNet to obtain an attention signal A (t), and then the A (t) is sent to the RFA to obtain a certain disease diagnosis result. Therefore, objective diagnosis of multiple neuropsychiatric diseases such as attention deficit hyperactivity disorder, autism, schizophrenia, bipolar affective disorder, Parkinson's disease, Alzheimer's disease, depressive disorder, anxiety disorder and the like can be realized by only adopting one short video.

The application discloses an amino thiazole compound and use thereof as a brain-permeable histamine H2 receptor agonist, and belongs to the field of medicines. The amino thiazole compound provided by the application has a structural general formula as shown in formula (I) and includes pharmaceutically acceptable salts. The amino thiazole compound has histamine H2 receptor agonistic activity and excellent blood-brain barrier permeability. Therefore, the amino thiazole compound can be applied to preparation of a medicine for treating diseases such as schizophrenia, mania, attention deficit hyperactivity disorder, binge eating or bulimia nervosa, autism, Parkinson's disease, ischemic brain injury and the like.

The invention provides an attention deficit hyperactivity disorder (ADHD) subtype recognition and evolution analysis method based on comparative learning, which comprises the following steps: acquiring brain functional magnetic resonance imaging data of an ADHD patient and a healthy person, and extracting low-frequency amplitude and functional connection multi-modal data from the brain functional magnetic resonance imaging data; inputting the multi-modal data into a feature coding module to generate potential feature representation of each modal; inputting the potential feature representation into a multi-view learning module, generating a projection semantic feature and a shared semantic feature, and minimizing the difference between the projection semantic feature and the shared semantic feature; performing hierarchical multi-agent regularization constraint on the shared semantic features; inputting the shared semantic features into a classifier for classification and recognition; and carrying out dimension reduction on the shared semantic features to obtain feature evolution trajectories from healthy people to different subtypes. According to the method, healthy people and disease subtypes can be identified, the characteristic dynamic evolution process from the healthy people to the subtypes is modeled, the neurological function heterogeneity of the disease is revealed, and a basis is provided for personalized precise diagnosis and treatment.